ArticleMolecular medicine (Cambridge, Mass.)2026
An ERRα-ZEB1 transcriptional signature predicts survival in triple-negative breast cancers.
Article in Molecular medicine (Cambridge, Mass.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTranscription factors (TFs) act together with co-regulators to modulate the expression of their target genes, which eventually dictates their pathophysiological effects. Depending on the co-regulator, TFs can exert different activities. The Estrogen Related Receptor α (ERRα) acts as a transcription factor that regulates several pathophysiological phenomena. In particular, interactions with PGC-1 co-activators are responsible for the metabolic activities of ERRα. In breast cancers however, ERRα exerts several tumor-promoting, metabolism-unrelated activities that do not depend on PGC-1, questioning the identity of the co-activators involved in these cancer-related effects.
methodsBio-computing methods were used to identify a potential ERRα coactivating factor in aggressive breast cancers. Bench experiments (qPCR, ChIP, proximity ligation assays) were used to validate the effect of the co-factor on ERRα transcriptional activity specifically in triple negative breast cancer (TNBC) cells. Predictive value of ERRα-co-factor target genes on the survival of TNBC patients was studied.
resultsZEB1 appears as a major ERRα co-factor, involved in increased expression of direct ERRα targets that induce cell migration in TNBCs. Experimental validations establish that ERRα and ZEB1 interact together and are bound to the promoters of the target genes that they transcriptionally coregulate. Further analyses show that the ERRα-ZEB1 downstream transcriptional signature can predict the survival of TNBC patients.
conclusionsOur approach combining bio-computing as well as experimental validation allows to propose a gene signature, the high expression of which predicts TNBC patient survival. Down modulation of these genes could be promising against TNBCs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.